Document Detail


Persistence of retinal function after intravitreal melphalan injection for retinoblastoma.
MedLine Citation:
PMID:  23143758     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: The risk/benefit profile of intravitreal melphalan injection for treatment of active vitreous seeds in retinoblastoma remains uncertain. We report clinical and electroretinography results after 6 months of one patient who has shown a favorable initial clinical response to intravitreal melphalan injections for treatment of refractory vitreous seeds. METHODS: Clinical case report. PATIENT: The patient presented at age 17 months with bilateral retinoblastoma [OD: International Classification (ICRB) group E, Reese-Ellsworth (R-E) class Vb; OS: ICRB D, R-E Vb] with no known prior family history. The right eye was enucleated primarily. The patient received systemic chemotherapy and extensive local treatment to the left eye. Ten months later, she presented with recurrent disease, including fine, diffuse vitreous seeds. Tumor control was established with intra-arterial chemotherapy and local treatment. Subsequent recurrence was treated with further intra-arterial chemotherapy, local treatment, and plaque radiotherapy with iodine-125. Persistent free-floating spherical vitreous seeds were treated with 4 cycles of intravitreal melphalan injection via the pars plana, with doses of 30, 30, 30, and 20 μg. RESULTS: After 6 months of follow-up, the left eye remained free of active tumor. Visual acuity was 20/40. Photopic ERGs amplitudes were unchanged compared with those recorded prior to the intravitreal injection treatments. CONCLUSIONS: Intravitreal melphalan injection for refractory spherical vitreous seeds of retinoblastoma with favorable tumor response is compatible with good central visual acuity and preservation of retinal function as indicated by photopic ERG recordings.
Authors:
Scott E Brodie; Francis L Munier; Jasmine H Francis; Brian Marr; Y Pierre Gobin; David H Abramson
Related Documents :
6716328 - Anticipatory nausea and vomiting associated with cancer chemotherapy.
24833028 - Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.
24074798 - The continued evidence from overviews: what is the clinical utility?
24733348 - Serum free light chain evaluation as a marker for the impact of intra-clonal heterogene...
22899468 - Streptozocin-based chemotherapy is not history in neuroendocrine tumours.
3807618 - Malignancies of the external ear canal and temporal bone: surgical techniques and results.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-11
Journal Detail:
Title:  Documenta ophthalmologica. Advances in ophthalmology     Volume:  -     ISSN:  1573-2622     ISO Abbreviation:  Doc Ophthalmol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370667     Medline TA:  Doc Ophthalmol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Ophthalmic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, scott.brodie@mssm.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Marine cyanobacterial fatty acid amides acting on cannabinoid receptors.
Next Document:  A comparison of the performance of three visual evoked potential-based methods to estimate visual ac...